Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: Pathogenetic implications and therapeutic options

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 12, 2014, Pages 8732-8739

  Quesada, Andrés E ^a   Nguyen, Nghia D ^a   Rios, Adan ^a   Brown, Robert E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Expression; Hematopathology; Morphoproteomics; Pathways; T cell lymphoma

Indexed keywords

CYCLOOXYGENASE 2; FASN PROTEIN, HUMAN; FATTY ACID SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIPROTEIN COMPLEX; PROTEIN KINASE B; SIRT1 PROTEIN, HUMAN; SIRTUIN 1; SOMATOMEDIN C RECEPTOR; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ADOLESCENT; ADULT; AGED; BIOSYNTHESIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PERIPHERAL T CELL LYMPHOMA; PHYSIOLOGY; PROTEOMICS; SIGNAL TRANSDUCTION; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYCLOOXYGENASE 2; FATTY ACID SYNTHASE, TYPE I; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; MULTIPROTEIN COMPLEXES; NF-KAPPA B; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SIRTUIN 1; TOR SERINE-THREONINE KINASES;

EID: 84921507536     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Gaulard P and de Leval L. Pathology of peripheral T-cell lymphomas: where do we stand? Semin Hematol 2014; 51: 5-16.
2. O'Leary H and Savage KJ. The spectrum of peripheral T-cell lymphomas. Curr Opin Hematol 2009; 16: 292-8.
3. Costello R, Sanchez C, Le Treut T, Rihet P, Imbert J, Sébahoun G. Peripheral T-cell lymphoma gene expression profiling and potential therapeutic exploitations. Br J Haematol 2010; 150: 21-7.
4. Brown RE. Morphogenomics and morphoproteomics: a role for anatomic pathology in personalized medicine. Arch Pathol Lab Med 2009; 133: 568-79.
5. Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood 2011; 117: 6756-67.
6. Vose J, Armitage J and Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124-30.
7. Moskowitz AJ, Lunning MA and Horwitz SM. How I treat the peripheral T-cell lymphomas. Blood 2014; 123: 2636-44.
8. Karlin L and Coiffier B. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. Semin Hematol 2014; 51: 25-34.
9. Shao W, Growney JD, Feng Y, O'Connor G, Pu M, Zhu W, Yao YM, Kwon P, Fawell S, Atadja P. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance. Int J Cancer 2010; 127: 2199-208.
10. Nihal M, Ahmad N and Wood GS. SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis. Cell Cycle 2014; 13: 632-40.
11. Brown RE, Bostrom B and Zhang PL. Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia. Ann Clin Lab Sci 2004; 34: 203-5.
12. Rosner M and Hengstschlager M. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Hum Mol Genet 2008; 17: 2934-48.
13. Rosner M, Siegel N, Valli A, Fuchs C, Hengstschläger M. mTOR phosphorylated at S2448 binds to raptor and rictor. Amino Acids 2010; 38: 223-8.
14. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-101.
15. Hresko RC and Mueckler M. mTOR. RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 2005; 280: 40406-16.
16. Tang F, Wu Q, Ikenoue T, Guan KL, Liu Y, Zheng P. A critical role for Rictor in T lymphopoiesis. J Immunol 2012; 189: 1850-7.
17. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005; 310: 1504-10.
18. Kim EH, Na HK, Kim DH, Park SA, Kim HN, Song NY, Surh YJ. 15-Deoxy-Delta12,14-prostaglandin J2 induces COX-2 expression through Akt-driven AP-1 activation in human breast cancer cells: a potential role of ROS. Carcinogenesis 2008; 29: 688-95.
19. Sundaresan NR, Pillai VB, Wolfgeher D, Samant S, Vasudevan P, Parekh V, Raghuraman H, Cunningham JM, Gupta M, Gupta MP. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal 2011; 4: ra46.
20. Rios-Moreno MJ, Jaramillo S, Díaz-Delgado M, Sánchez-León M, Trigo-Sánchez I, Padillo JP, Amérigo J, González-Cámpora R. Differential activation of MAPK and PI3K/AKT/mTOR pathways and IGF1R expression in gastrointestinal stromal tumors. Anticancer Res 2011; 31: 3019-25.
21. Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A, Testa JR. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 2005; 24: 3574-82.
22. Kane LP, Mollenauer MN, Xu Z, Turck CW, Weiss A. Akt-dependent phosphorylation specifically regulates Cot induction of NF-kappa B-dependent transcription. Mol Cell Biol 2002; 22: 5962-74.
23. Cheng J, Phong B, Wilson DC, Hirsch R, Kane LP. Akt fine-tunes NF-kappaB-dependent gene expression during T cell activation. J Biol Chem 2011; 286: 36076-85.
24. Cai Q, Deng H, Xie D, Lin T, Lin T. Phosphorylated AKT protein is overexpressed in human peripheral T-cell lymphomas and predicts decreased patient survival. Clin Lymphoma Myeloma Leuk 2012; 12: 106-12.
25. Odqvist L, Sánchez-Beato M, Montes-Moreno S, Martín-Sánchez E, Pajares R, Sánchez-Verde L, Ortiz-Romero PL, Rodriguez J, Rodríguez-Pinilla SM, Iniesta-Martínez F, Solera-Arroyo JC, Ramos-Asensio R, Flores T, Palanca JM, Bragado FG, Franjo PD, Piris MA. NIK controls classical and alternative NF-kappaB activation and is necessary for the survival of human T-cell lymphoma cells. Clin Cancer Res 2013; 19: 2319-30.
26. Paydas S, Ergin M, Erdogan S, Seydaoglu G. Cyclooxygenase-2 expression in non-Hodgkin's lymphomas. Leuk Lymphoma 2007; 48: 389-95.
27. Chen CS, Weng SC, Tseng PH, Lin HP, Chen CS. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 2005; 280: 38879-87.
28. Suzuki M, Endo M, Shinohara F, Echigo S, Rikiishi H. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells. Cancer Chemother Pharmacol 2009; 64: 1115-22.
29. Eades G, Yao Y, Yang M, Zhang Y, Chumsri S, Zhou Q. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem 2011; 286: 25992-6002.
30. Zhu Z, Jiang W, McGinley JN, Thompson HJ. Defining the role of histone deacetylases in the inhibition of mammary carcinogenesis by dietary energy restriction (DER): effects of suberoylanilide hydroxamic acid (SAHA) and DER in a rat model. Cancer Prev Res (Phila) 2013; 6: 290-8.
31. Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 2009; 114: 2926-35.
32. Abrahao AC, Giudice FS, Sperandio FF, Pinto Junior Ddos S. Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma. J Oral Pathol Med 2013; 42: 793-8.
33. Sareddy GR, Geeviman K, Ramulu C, Babu PP. The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-kappaB pathway. J Neurooncol 2012; 106: 99-109.
34. Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 2010; 17: 351-60.
35. Roccaro AM, Vacca A and Ribatti D. Bortezomib in the treatment of cancer. Recent Pat Anticancer Drug Discov 2006; 1: 397-403.
36. Yang F, Jove V, Chang S, Hedvat M, Liu L, Buettner R, Tian Y, Scuto A, Wen W, Yip ML, Van Meter T, Yen Y, Jove R. Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-κB signaling, and synergizes with an ERK inhibitor. Cancer Biol Ther 2012; 13: 349-57.
37. Befani CD, Vlachostergios PJ, Hatzidaki E, Patrikidou A, Bonanou S, Simos G, Papandreou CN, Liakos P. Bortezomib represses HIF-1alpha protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. J Mol Med (Berl) 2012; 90: 45-54.
38. Brown RE and Law A. Morphoproteomic demonstration of constitutive nuclear factor-kappaB activation in glioblastoma multiforme with genomic correlates and therapeutic implications. Ann Clin Lab Sci 2006; 36: 421-6.
39. Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, Lee J, Ryoo BY, Ko YH, Huh J, Yang WI, Kim HK, Min SK, Lee SS, Do IG, Suh C, Kim WS; Consortium for Improving Survival of Lymphoma (CISL) investigators. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer 2012; 48: 3223-31.
40. Quesada AE, Brown RE, Rios A, Nguyen ND. Expression of Constitutively Activated NF-κB/mTORC Pathway Proteins and Response to CHOP Plus Bortezomib in a Patient with Angioimmunoblastic Peripheral T-cell Lymphoma. Clin Lymphoma Myeloma Leuk 2014; 14 Suppl: S87-9.